Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

Interleukin-5 (IL-5) is essential for the formation of eosinophils, which are thought to have a major role in the pathogenesis of asthma and other allergic diseases. We aimed to assess the effects of monoclonal antibody to IL-5 on blood and sputum eosinophils, airway hyperresponsiveness, and the lat...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2000-12, Vol.356 (9248), p.2144-2148
Main Authors: Leckie, Margaret J, Brinke, Anneke ten, Khan, Jamey, Diamant, Zuzana, O'Connor, Brian J, Walls, Christine M, Mathur, Ashwini K, Cowley, Hugh C, Chung, K Fan, Djukanovic, Ratko, Hansel, Trevor T, Holgate, Stephen T, Sterk, Peter J, Barnes, Peter J
Format: Article
Language:English
Subjects:
Adult
Allergens
Allergies
Analysis of Variance
Antibodies, Monoclonal - therapeutic use
Asthma
Asthma - therapy
Biological and medical sciences
Blood pressure
Bronchial Provocation Tests
Double-Blind Method
Eosinophils - metabolism
Histamine
Histamine - blood
Humans
Infusions, Intravenous
Inhalation
Injection
Interleukin-5 - antagonists & inhibitors
Leukocyte Count
Lungs
Lymphocytes
Male
Medical sciences
Parasites
Pharmacology. Drug treatments
Respiratory function
Respiratory system
Sputum - cytology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin-5 (IL-5) is essential for the formation of eosinophils, which are thought to have a major role in the pathogenesis of asthma and other allergic diseases. We aimed to assess the effects of monoclonal antibody to IL-5 on blood and sputum eosinophils, airway hyperresponsiveness, and the late asthmatic reaction to inhaled allergen in patients with mild asthma. We did a double-blind randomised placebo-controlled trial, in which a single intravenous infusion of humanised (IgG-k) monoclonal antibody to IL-5 (SB-240563) was given at doses of 2·5 mg/kg (n=8) or 10·0 mg/kg (n=8). The effects of treatment on responses to inhaled allergen challenge, sputum eosinophils, and airway hyper-responsiveness to histamine were measured at weeks 1 and 4 with monitoring of blood eosinophil counts for up to 16 weeks. Monoclonal antibody against IL-5 lowered the mean blood eosinophil count at day 29 from 0·25x10 9 /L (95% CI 0·16-0·34) in the placebo group to 0·04x10 9 /L (0·00-0·07) in the 10 mg/kg group (p
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(00)03496-6